Bioretec concluded change negotiations for production
Summary
- Bioretec concluded change negotiations to streamline its Finnish production, resulting in the termination of three employees and targeting additional annual savings of 0.2 MEUR.
- The company had previously identified oversized production investments relative to business development, necessitating further adjustments to align with actual demand.
- Despite the limited savings in euro terms, these measures aim to adjust the cost structure to match demand and protect cash reserves, with a focus on ramping up RemeOs sales in the US and Europe.
- The company's financial forecast for 2026 includes revenue of approximately 5.1 MEUR and an adjusted EBIT of -7.1 MEUR, indicating a clearly loss-making earnings level.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 6/18/2026 at 8:13 am EEST.
Bioretec announced on Wednesday that it had concluded change negotiations focused on its Finnish production function, which the company initiated in early June to streamline operations and improve profitability. A total of 12 employees were included in the scope of the negotiations, and as a result, the employment of three of those employees will be terminated. The negotiations aimed to achieve additional annual savings of approximately 0.2 MEUR, in addition to the previously announced savings target of approximately 0.4 MEUR. We will account for the decreasing cost level in our estimates in connection with the next update.
Cost structure to be adjusted to reflect actual demand
These measures align with the production adjustment process that the company initiated last fall. Bioretec already stated in November 2025 that investments made in production have proven to be oversized in relation to the actual development of the business. At that time, the negotiations resulted in one person being made redundant and five people being temporarily laid off, but according to the company, these measures alone were not enough to adjust production to the current volume. The company had built up its production capacity in anticipation of faster ramp-up of sales of the RemeOs product family, but this has progressed more slowly than anticipated.
The targeted additional savings of 0.2 MEUR are limited in euro terms within the company’s overall cost structure relative to its clearly loss-making earnings level (our forecast for 2026: revenue of approximately 5.1 MEUR, adj. EBIT: -7.1 MEUR). However, the measures are moving in the right direction: the company appears to be adjusting its cost structure tightly to match actual demand while protecting the cash reserves raised through the share issue in the spring. In the short term, the focus remains on ramping up RemeOs sales in the US and Europe.
Login required
This content is only available for logged in users
Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.
Read more on company pageKey Estimate Figures18.05.
| 2025 | 26e | 27e | |
|---|---|---|---|
| Revenue | 3.5 | 5.1 | 7.9 |
| growth-% | -22.5 % | 45.6 % | 54.1 % |
| EBIT (adj.) | -8.7 | -7.1 | -5.5 |
| EBIT-% (adj.) | -246.6 % | -138.0 % | -69.6 % |
| EPS (adj.) | -0.31 | -0.01 | -0.00 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |
Forum discussions
